🇺🇸

IPO Capital Markets

· daily

US IPO Pipeline SEC S-1 Filings — July 15, 2026

The IPO pipeline digest for July 15, 2026, reveals a bifurcated market: two clinical-stage biotech IPOs (Vogenx, Braveheart Bio) seek to capitalize on promising drug candidates, while two blank-check and restructuring filings (Churchill Capital XIII, Sono Group) reflect ongoing SPAC and cross-border M&A activity. However, the most critical theme is the severe financial distress among several filers—authID Inc. and Vogenx both report cash balances under $1.2M with going-concern doubts, and Rallybio’s cash burn rate has accelerated 26% YoY, necessitating a dilutive merger. Period-over-period trends show a mixed picture: Vogenx cut operating expenses 39% YoY but still faces a $1.4M working capital deficit, while Rallybio’s R&D spend jumped 26% YoY with no revenue. Forward-looking statements across filings highlight heavy reliance on IPO proceeds or M&A for survival, with no insider buying detected in any filing—a bearish signal for management conviction. The pipeline is dominated by high-risk, high-reward biotech plays and capital-intensive restructurings, with limited visibility on near-term profitability.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 14, 2026

The sole filing in this IPO Pipeline digest is from Attovia Therapeutics, a pre-revenue biopharmaceutical company seeking to go public on Nasdaq. The company has no approved products, no revenue, and significant accumulated losses, but holds a strong cash position of $132.6 million to fund its pipeline. The mixed sentiment reflects the high-risk, high-reward profile typical of early-stage biotech IPOs. With no period-over-period comparisons, insider activity, or forward guidance available, the intelligence is limited to the company's financial health and clinical-stage risks. The IPO represents a pure speculative opportunity for investors willing to bet on its lead candidates ATTO-1310 and ATTO-2306.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 13, 2026

The IPO pipeline is active with four new S-1 filings, highlighting a mix of healthcare technology, industrial laser, and SPAC offerings. The filings reveal a cautious market sentiment, with two companies (Nuburu and N2OFF) showing significant ongoing losses and negative sentiment, while Avalon GloboCare and Material Resource Acquisition Corp. present neutral profiles. Period-over-period data is limited, but N2OFF's pro forma financials show a net loss of $6.841 million with no revenue from its recent acquisition, indicating operational challenges. Insider activity is sparse, but management changes at Avalon GloboCare and complex capital structures at Nuburu and N2OFF signal potential governance and dilution risks. The SPAC offering from Material Resource Acquisition Corp. provides a traditional blank-check structure with a $200 million target, reflecting continued interest in SPACs despite regulatory scrutiny. Overall, the pipeline is weighted towards riskier, early-stage companies, with only the SPAC offering a more conventional investment profile.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 10, 2026

The IPO pipeline on July 10, 2026, is dominated by a wave of S-1 filings from companies in transition—reverse mergers, SPAC combinations, and pivots into digital assets and AI—rather than traditional growth IPOs. A clear theme is the prevalence of resale registrations (6 of 11 filings) that offer no primary capital to issuers, creating significant share overhang and dilution risk for investors. Period-over-period data reveals a stark contrast: Apnimed's revenue surged 2,636% YoY from a related-party deal, while Holtec Nuclear saw a 7.0% revenue decline and a $23.7M operating loss at its Palisades segment. Capital allocation is uniformly non-existent, with no dividends or buybacks across the cohort, and insider activity is absent from all filings. The most critical development is the convergence of digital asset strategies—Avalanche Treasury (SPAC + crypto) and iPower (bitcoin/ethereum treasury)—signaling a new wave of crypto-exposed public entities, albeit with pre-revenue or untested models. Overall, the pipeline is heavy on risk and dilution, with few clear bullish catalysts, making selective, catalyst-driven scrutiny essential.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 09, 2026

The July 9, 2026, IPO pipeline is dominated by a mix of traditional SPAC, development-stage, and distressed issuers, alongside a major M&A-driven registration from NextEra Energy. The most significant theme is the surge in capital markets activity tied to transformative M&A, with the NextEra-Dominion S-4 representing a $60B+ implied deal and the Pulmatrix-Eos merger targeting a high-risk biotech combination. On the IPO front, Southern Cross Acquisition II (SPAC) and Leef Brands (cannabis) provide contrasting risk profiles, while Mitesco and Jaovi represent deeply distressed or micro-cap filings with going-concern warnings. Period-over-period data reveals mixed revenue trends: Leef Brands grew 15% YoY but with uneven segment performance, while Pulmatrix showed a 15% revenue increase but widening losses. The absence of insider trading activity in most filings is notable, though the Mitesco filing implies significant insider dilution via debt conversion. Overall, the pipeline signals a bifurcated market where quality issuers (NextEra) use registered exchanges for debt, while speculative and distressed entities test the IPO window.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 08, 2026

The IPO pipeline for July 8, 2026, is dominated by three distinct offerings: a traditional SPAC (Catalyst Acquisition Corp.), a distressed biotech follow-on (AEON Biopharma), and a controlled-company resale registration (Evolution Metals & Technologies Corp.). The SPAC market shows continued activity with a $200M blank-check IPO targeting media and gaming, though no target has been identified. AEON Biopharma's offering is highly dilutive (immediate dilution of $0.83 per share) and carries existential risk from a potential NYSE American delisting by August 3, 2026, with milestone warrants that are speculative and time-bound. Evolution Metals' resale filing signals potential overhang from a convertible debenture conversion, with the company's 70.18% controlling shareholder structure limiting governance protections. Across the pipeline, period-over-period comparisons are limited as these are initial filings, but the absence of any revenue or operational history for the SPAC and the negative tangible book value trend for AEON highlight a pipeline skewed toward high-risk, speculative structures. The most critical development is AEON's delisting deadline, which creates a binary catalyst for the stock within the next month.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 06, 2026

The IPO pipeline is active with three distinct filings on July 6, 2026, each representing a different stage of capital markets activity: a de-SPAC-like merger (Weatherford/NCS), a corporate spin-off (Honeywell Aerospace), and a traditional IPO (Syntiant). The filings reveal a mixed sentiment environment, with no clear bullish or bearish consensus. Key period-over-period trends are limited due to the nature of these filings (initial registrations), but forward-looking data and insider activity provide actionable insights. The most critical development is Syntiant's IPO, which introduces a dual-class structure that will concentrate voting control with founders, a potential governance risk for minority investors. The Honeywell Aerospace spin-off offers a unique opportunity to gain pure-play exposure to a diversified aerospace and defense leader, with executive compensation tied to performance metrics. The Weatherford/NCS merger presents a complex arbitrage opportunity with a fixed-exchange ratio and termination fees, but regulatory risks and insider conflicts require careful monitoring. Overall, the pipeline suggests a moderate level of IPO activity with a focus on strategic transactions rather than pure growth stories.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 02, 2026

The IPO pipeline is surging with 12 new filings on July 2, 2026, dominated by SPACs (4 of 13) and traditional IPOs (Jersey Mike's, Scribe Therapeutics, Dear Industrial Gas, Cycurion). The most notable trend is the extreme financial fragility among several IPO candidates: Scribe Therapeutics shows a 5x widening in net losses and negative working capital, while Dear Industrial Gas has zero revenue and no governance structure. Period-over-period data reveals a stark contrast between established operators like Jersey Mike's (50% cumulative same-store sales growth 2020-2025) and pre-revenue biotechs. The M&A pipeline is equally active with three major S-4 filings: Sysco's $1.164B termination-fee-laden acquisition of Jetro Restaurant Depot, Olin-Huntsman's merger of equals, and Gentherm's Reverse Morris Trust acquisition of Modine's Performance Technologies. Insider activity is notably absent across all filings, but capital allocation signals are mixed—Jersey Mike's proceeds will repay debt while SPACs offer no near-term returns. The most critical development is the concentration of SPAC filings (B&R Technology, Laris Growth, Gold Mountain) targeting $600M+ in aggregate proceeds, signaling renewed blank-check appetite despite regulatory headwinds.

13 high priority 13 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 01, 2026

The IPO pipeline for July 1, 2026, is dominated by SPAC-related activity (Three Lions Acquisition Corp., Exascale Labs/DBoral ARC) and distressed or early-stage operating companies (Actelis Networks, OneMedNet, Asia AI Group). Period-over-period data reveals a stark contrast: OneMedNet shows 25% YoY revenue growth but widening net losses (+18.4% YoY), while Actelis Networks faces a liquidity crisis tied to a single selling stockholder and Nasdaq delisting. The Exascale Labs S-4 filing provides detailed financials for a SPAC merger, but no period-over-period trends are available. Asia AI Group is a pre-revenue shell with zero compensation for executives, raising governance red flags. The most critical development is the shift from acquisition to collaboration for Actelis Networks, signaling a strategic retreat. Portfolio-level themes include high dilution risk (Three Lions, Actelis, OneMedNet), reliance on SPAC trust proceeds for exits, and a lack of insider buying across all filings, suggesting limited management conviction.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 30, 2026

The IPO pipeline is active with six filings, but the underlying financial health of the issuers is severely mixed, with a clear pattern of widening losses and heavy reliance on dilutive financing. Matternet (drone logistics) and Factorial Energy (via Cartesian Growth Corp III) both reported expanding net losses, with Factorial's Q1 2026 loss growing 35.7% YoY. The most critical development is the S-4 filing from Angel Studios, signaling a complex multi-party merger to go public, while urban-gro's S-1 reveals a deeply troubled entity with a $120.6M accumulated deficit and extreme geographic revenue concentration (82% from Sri Lanka). A portfolio-level theme is the prevalence of 'going concern' risks and negative retained earnings, suggesting many of these IPOs are distressed recapitalizations rather than growth stories. Insider activity data was sparse, but the lack of bonuses and 401(k) contributions at AMASS BRANDS signals cash conservation. The pipeline is tilted toward high-risk, capital-intensive ventures with no clear path to profitability, demanding extreme due diligence from investors.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 29, 2026

The IPO pipeline is active with 10 filings, including 4 traditional IPOs (Forgent Power Solutions, SeeQC, Exyn Technologies, Ionic Digital), 3 S-1 resale registrations (Capstone Holding, Classover Holdings, BiomX), 2 S-4 merger registrations (Equity Residential, FS Bancorp), and 1 follow-on offering (Capstone Holding second filing). Key themes include high dilution risk from resale registrations and equity lines, mixed financial health with revenue growth but net losses, and significant insider activity absent in most filings. The most critical developments are Forgent Power Solutions' IPO with 7.1% revenue growth but a net loss swing, Ionic Digital's direct listing with no lock-ups, and FS Bancorp's accretive bank merger. Portfolio-level patterns show a tilt toward pre-revenue or loss-making companies in emerging tech (quantum, drones, biotech-defense), while traditional sectors (REITs, banks) show stability. Period-over-period trends reveal revenue growth in Forgent (7.1% YoY) and backlog expansion, but margin compression in BiomX and Capstone due to restructuring costs.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 26, 2026

The June 26, 2026 IPO pipeline is dominated by high-risk, transformative transactions: three companies (Professional Diversity Network, Jupiter Neurosciences, Coeptis Therapeutics) are pivoting into unrelated or speculative businesses as going concerns, probing the lower end of capital markets for survival financing. A fourth blank-check company (AMR Resources) targets a commodity sector with non-binding institutional interest, while Hawthorn Bancshares' merger creates a regional banking powerhouse with accretive earnings. Period-over-period data reveals a common theme of cash burn and negative margins, with Coeptis posting an accumulated deficit of $113.9M and Jupiter showing no meaningful product revenue despite starting shipments. Capital allocation is minimal, with no dividends or buybacks reported; instead, funds are directed toward acquisitions and operational pivots. Insider trading is absent across filings, limiting confirmation of management conviction, but forward-looking data provides key catalysts (e.g., Jupiter's Phase IIa results in Q2 2027, Hawthorn's merger close, Coeptis's breakeven DOGE price). The most critical development is Coeptis's cryptocurrency mining viability at $0.085/DOGE vs. a $0.13-$0.15 breakeven, threatening immediate operational risk.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 26, 2026

The June 26, 2026 SEC filings reveal a bifurcated IPO/pipeline landscape with three distinct themes: a wave of speculative, high-risk SPAC and micro-cap capital raises targeting digital assets and penny-stock restructuring; a traditional, accretive regional bank merger in the financial sector; and a clinical-stage biotech struggling to stay afloat. Three of the five filers (Professional Diversity Network, Coeptis Therapeutics, and Jupiter Neurosciences) share a common pattern of deep financial distress, with going-concern warnings, chronic net losses, and pivots into unproven or highly volatile asset classes like cryptocurrency mining and tokenization. Meanwhile, AMR Resources Acquisition Corp. represents a blank-check vehicle raising $250M, providing a conduit for private mineral-resource companies to go public, but carries high pre-deal uncertainty. In contrast, Hawthorn Bancshares' bank merger demonstrates tangible pro forma EPS accretion (+2.3% to $3.52) and a clear, cost-synergy-driven integration plan within a stable regulatory framework. The most critical takeaway is that insider activity is absent across all deals, and forward-looking guidance is either nonexistent or heavily caveated, forcing investors to rely on disclosed breakeven thresholds (e.g., Dogecoin price targets) and high-burn-rate timelines as the primary valuation anchors.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 25, 2026

The IPO pipeline is active with four S-1/S-4 filings on June 25, 2026, spanning utilities, community banking, sustainable fashion, and biotech. A key theme is the predominance of secondary offerings by selling shareholders (Lincoln Bancorp, Reformation Inc.), indicating early investors seeking liquidity rather than primary capital raises. Period-over-period data reveals a mixed financial picture: Jersey Central Power & Light shows a concerning 29.4% decline in short-term cash investments, while Creative Medical Technology remains pre-revenue with no commercial activity. Reformation Inc. stands out as the highest-quality IPO candidate given its consumer brand and NYSE listing plans, but the lack of financial disclosures in the preliminary filing limits analysis. The biotech sector is represented by Creative Medical Technology, which carries high risk/reward given regulatory milestones but zero revenue. Overall, the pipeline lacks a blockbuster IPO, suggesting cautious market sentiment for new issuances.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 24, 2026

The IPO pipeline on June 24, 2026, features three filings: iSpecimen Inc., a biospecimen provider with deteriorating revenue and going-concern doubts; Liminatus Pharma, a pre-revenue biotech with heavy related-party debt; and Hoya Acquisition Corp. I, a blank-check SPAC with no operational history. iSpecimen's period comparisons reveal a sharp 79% YoY revenue decline and widening quarterly losses, signaling financial distress. Liminatus carries a $112M accumulated deficit and no disclosed revenue, raising viability concerns. Hoya's SPAC structure offers a speculative IPO opportunity but carries standard blank-check risks. Overall, the pipeline lacks high-quality issuers, with negative sentiment dominating (2 negative, 1 neutral), suggesting a cautious market reception for new listings.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 23, 2026

On a very quiet session for the IPO Pipeline with only one filing, the spotlight falls on Spin AI Inc., a micro-cap company attempting a $100,000 best-efforts IPO. The S-1 reveals a company with zero revenue history, a net loss of $108 as of March 31, 2026, and only $365 in cash against a going-concern warning from auditors. The offering price of $0.01 per share was arbitrarily set, and there is no minimum subscription or escrow, meaning investor funds are immediately accessible to the company without any guarantee of the offering's completion. Despite the commercial launch of its SPIN AI platform on June 7, 2026, the company has only three active subscribers, with two more expected to start in November 2026. This filing underscores a pattern of highly speculative, pre-revenue companies attempting to access public markets, but the negligible amount raised and the company's financial fragility make it a high-risk outlier rather than a bellwether for broader IPO activity. The overwhelming signal is one of extreme caution, with no positive period-over-period trends or insider activity to offset the fundamental weaknesses.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 22, 2026

The June 22, 2026, SEC filings reveal a concentrated wave of IPO registrations across infrastructure, tech, and medtech, with 8 new S-1s and 1 follow-on. Revenue growth is a common theme—MOBIX LABS (+50% YoY) and Ambiq Micro (+25% YoY) lead—but widening losses and cash burn raise sustainability concerns. Period-over-period data shows a clear pattern: revenue expansion at the expense of profitability, with Creatd posting a 30% revenue decline and a 335% net loss surge. Governance risks are prominent: dual-class structures at Gloo Holdings and VenHub Global concentrate voting power, while Catheter Precision's related-party warrants remain unexercisable pending stockholder approval. Financial distress flags include VenHub's $98.78M accumulated deficit and going concern doubt, and Aethlon's manufacturing delays and trial cancellations. Despite mixed sentiment, the pipeline offers high

9 high priority 9 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 18, 2026

The IPO pipeline is active with six filings on June 18, 2026, spanning blank-check companies, energy solutions, nuclear power, AI, and biotech. Revenue growth is a common theme, with OZOP Energy Solutions showing a 200% YoY increase but widening net losses, while Goodvision AI also reports revenue growth amid net losses. Standard Nuclear and Bleichroeder Acquisition Corp. III are pre-revenue, relying on IPO proceeds for future operations. Insider activity is limited, but significant dilution risks are flagged in Bleichroeder and AIM ImmunoTech. Forward-looking data highlights upcoming catalysts: Standard Nuclear's NYSE listing, AIM ImmunoTech's Phase 3 trial design, and OZOP's customer concentration risks. Capital allocation is minimal, with no dividends or buybacks. Portfolio-level patterns show a mix of growth-stage companies with high cash burn and speculative SPACs, suggesting a cautious approach for investors.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 16, 2026

The IPO pipeline on June 16, 2026, is dominated by three SPAC filings (OceanLight Acquisition Corp, Market Technology Acquisition Corp) and one blank-check business combination (Bio Green Med Solution), alongside a traditional IPO from Csquare, Inc. with significant governance concerns. All four filings lack period-over-period revenue trends or operational metrics, as they are pre-revenue or early-stage entities, limiting traditional growth analysis. The most critical development is the high concentration risk in Bio Green Med Solution, where Future NRG Sdn Bhd derived 100% of its revenue from a single customer in both 2024 and 2025, and 100% of accounts receivable as of March 31, 2026, indicating extreme dependency. Market Technology Acquisition Corp's sponsor acquired 7,666,667 founder shares for only $25,000, creating massive dilution risk for public shareholders, while OceanLight's focus on China-based targets introduces geopolitical and regulatory uncertainty. Csquare's post-IPO governance structure, with Brookfield controlling a majority voting power, exempts it from key NYSE independence requirements and includes staggered board terms and anti-takeover provisions that limit shareholder rights. The overall pipeline signals a surge in SPAC activity with elevated risk profiles, particularly around concentration, dilution, and regulatory exposure.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 15, 2026

The IPO pipeline for mid-June 2026 is dominated by a wave of blank-check companies (SPACs) seeking to raise a combined $150M+ in blind pools, alongside a mix of secondary offerings and complex biotech/energy mergers. A key period-over-period trend is the deteriorating financial health of pre-revenue firms: GigCapital7's net losses widened 25% YoY, and XCF Global's merger partner DevvStream is a going concern with only 2 employees. The most critical development is the sheer volume of SPAC filings (Leader's Advantage, Osprey III, GigCapital7) which, while providing IPO capital, carry high dilution risks for public shareholders due to nominal sponsor stakes. A portfolio-level pattern is the prevalence of 'controlled company' structures and equity line of credit (ELOC) financings, signaling that many issuers are prioritizing capital access over shareholder governance. The market implication is a bifurcated pipeline: high-risk, high-dilution SPACs and pre-revenue biotechs vs. established platforms like Pattern Group executing secondary sales.

7 high priority 7 total filings